Q-omics provides the consensus-scored WBP1LP2 profile across patient tissues and cancer cell-line models. WBP1LP2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, WBP1LP2 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, WBP1LP2 RNA expression shows 15,869 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and THCA as cancer lineages where WBP1LP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WBP1LP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WBP1LP2 survival associations across molecular data types. WBP1LP2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WBP1LP2 RNA expression–survival associations across cancer types. High WBP1LP2 expression shows unfavorable associations in UVM, CESC, MESO, LGG and KIRP, but favorable associations in UCEC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for WBP1LP2 RNA expression.
This table summarizes WBP1LP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for WBP1LP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WBP1LP2 shows lower tumor expression in THCA and LUSC and higher tumor expression in KIRC, KIRP, LIHC and HNSC. The THCA box plot shows higher WBP1LP2 RNA expression in normal versus tumor tissue (log2 FC = −1.077, t-test p < 0.001).
This table shows molecular features associated with WBP1LP2 in patient tissues and cancer cell lines. In patient samples, WBP1LP2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
